Polymeric alginate nanoparticles containing the local anesthetic bupivacaine

dc.creatorGrillo, R
dc.creatorde Melo, NFS
dc.creatorde Araujo, DR
dc.creatorde Paula, E
dc.creatorRosa, AH
dc.creatorFraceto, LF
dc.date2010
dc.dateNOV
dc.date2014-11-16T22:47:34Z
dc.date2015-11-26T16:25:49Z
dc.date2014-11-16T22:47:34Z
dc.date2015-11-26T16:25:49Z
dc.date.accessioned2018-03-28T23:06:32Z
dc.date.available2018-03-28T23:06:32Z
dc.identifierJournal Of Drug Targeting. Informa Healthcare, v. 18, n. 9, n. 688, n. 699, 2010.
dc.identifier1061-186X
dc.identifierWOS:000282516600005
dc.identifier10.3109/10611861003649738
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/70700
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/70700
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/70700
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1268713
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionBupivacaine (BVC; S75-R25, NovaBupi<SU (R)</SU) is an amide-type local anesthetic. Sodium alginate is a water-soluble linear polysaccharide. The present study reports the development of alginate/bis(2-ethylhexyl) sulfosuccinate (AOT) and alginate/chitosan nanoparticle formulations containing BVC (0.5%). The amounts of BVC associated in the alginate/AOT and alginate/chitosan nanoparticles were 87 +/- 1.5 and 76 +/- 0.9%, respectively. The average diameters and zeta potentials of the nanoparticles were measured for 30 days, and the results demonstrated the good stability of these particles in solution. The in vitro release kinetics showed a different behavior for the release profile of BVC in solution, compared with BVC-loaded alginate nanoparticles. In vitro and in vivo assays showed that alginate-chitosan BVC (BVC(ALG-CHIT)) and alginate-AOT BVC (BVC(ALG-AOT)) presented low cytotoxicity in 3T3-fibroblasts, enhanced the intensity, and prolonged the duration of motor and sensory blockades in a sciatic nerve blockade model.</.
dc.description18
dc.description9
dc.description688
dc.description699
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionFundação para o Desenvolvimento da UNESP (FUNDUNESP)
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionFAPESP [06/00121-9]
dc.descriptionFUNDUNESP [06/00121-9, 07/00127-0, 08/01222-9]
dc.languageen
dc.publisherInforma Healthcare
dc.publisherLondon
dc.publisherInglaterra
dc.relationJournal Of Drug Targeting
dc.relationJ. Drug Target.
dc.rightsfechado
dc.rightshttp://informahealthcare.com/userimages/ContentEditor/1255620309227/Copyright_And_Permissions.pdf
dc.sourceWeb of Science
dc.subjectBupivacaine
dc.subjectpolymeric nanoparticles
dc.subjectalginate
dc.subjectin vivo
dc.subjectin vitro
dc.subjectLoaded Biodegradable Nanospheres
dc.subjectSciatic-nerve Blockade
dc.subjectDrug-release
dc.subjectQuantitative-determination
dc.subjectInclusion Complex
dc.subjectDelivery Systems
dc.subjectMatrix Tablets
dc.subjectLidocaine
dc.subjectMicroparticles
dc.subjectNanocapsules
dc.titlePolymeric alginate nanoparticles containing the local anesthetic bupivacaine
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución